Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended July 1, 2006 (First Quarter of Fiscal Year 2007)
Business Overview: The company designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood, along with related single-use disposables and data management software. Operations are conducted globally, with approximately 58% of revenue generated outside the United States.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 FY2007 (Ended July 1, 2006) |
Q1 FY2006 (Ended July 2, 2005) |
|---|---|---|
| Net Revenues | $110,674 | $103,173 |
| Gross Profit | $57,373 | $54,524 |
| Gross Margin | 51.8% | 52.8% |
| Operating Income | $15,043 | $18,495 |
| Operating Margin | 13.6% | 17.9% |
| Net Income | $11,308 | $12,884 |
| Diluted EPS | $0.40 | $0.47 |
| Cash and Cash Equivalents | $260,031 | $198,067 |
| Working Capital | $343,695 | $275,722 |
| Net Cash Provided by Operating Activities | $17,509 | $11,759 |
| Total Debt (Current + Long-term) | $35,061 | Not explicitly stated for prior period |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.3% year-over-year, driven by a 7.8% increase in disposable revenues. Growth was led by Plasma (+16.9%), Red Cell (+25.4%), and OrthoPAT (+28.9%) product lines. This was partially offset by a decline in Blood Bank disposables (-4.1%) and Equipment revenue (-8.2%).
- Profitability Decline: Despite revenue growth, Operating Income decreased 18.7% and Net Income decreased 12.2%. This was primarily due to a 17.5% increase in operating expenses.
- Expense Drivers: The increase in Selling, General, and Administrative (SG&A) expenses was driven by:
- Adoption of SFAS No. 123R (Stock-based compensation), accounting for approximately 47% of the operating expense increase ($3.0 million expense recognized).
- Restructuring costs of $1.6 million related to international sales and service reorganization.
- Expansion of the patient sales force to support direct selling strategies.
- Currency Impact: Foreign exchange fluctuations provided a favorable impact of 0.3% on revenues and 4.8% on operating income. Without currency effects, operating income would have declined 23.6%.
Guidance, Outlook, and Risks
- Restructuring: The company expects total restructuring costs for the fiscal year to range between $3 million and $4 million (pre-tax), with approximately $2.5 million in employee-related costs and up to $1.5 million in facility closure costs.
- Acquisition (Subsequent Event): On July 18, 2006, the company acquired the remaining shares of Arryx, Inc. for $26 million. This is expected to result in an in-process research and development charge of up to $16 million, which will increase the reported annual tax rate.
- Tax Rate: The effective tax rate for the quarter was 35.6%. Management expects the annual rate to be approximately 35.5% for the remainder of the fiscal year, excluding the impact of the Arryx acquisition charge.
- Risks: Key risks include foreign currency exchange rate fluctuations (hedged via forward contracts), regulatory uncertainties, competitive pressures in the plasma market, and the impact of industry consolidation.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the sustainability of earnings given the one-time adoption of SFAS 123R, which added $3.0 million in non-cash expense this quarter.
- Restructuring Execution: Monitor the execution of the $3–$4 million restructuring plan and its impact on future operating margins.
- Arryx Acquisition Integration: Assess the financial impact of the $16 million in-process R&D charge and the integration of Arryx technology.
- Japan Market Exposure: Review trends in the Japanese market, where revenue declined due to lower collections by the Japan Red Cross Society and competitive pressures.
- Currency Hedging Effectiveness: Evaluate the company's ability to maintain margins given that 58% of sales are in foreign currencies (Yen and Euro).